Fibrogenic impact of high serum glucose in chronic hepatitis C. (Q44182966)

30 November 2017

Fibrogenic impact of high serum glucose in chronic hepatitis C. (English)

1 reference

30 November 2017

1 reference

5

1 reference

30 November 2017

Vlad Ratziu

1

1 reference

30 November 2017

Mona Munteanu

2

1 reference

30 November 2017

Fréderic Charlotte

3

1 reference

30 November 2017

Luminita Bonyhay

4

1 reference

30 November 2017

LIDO Study Group

6

1 reference

30 November 2017

1 December 2003

1 reference

30 November 2017

Journal of Hepatology

1 reference

30 November 2017

39

1 reference

30 November 2017

6

1 reference

30 November 2017

1049-1055

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

45-year follow-up of hepatitis C virus infection in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Excess weight risk factor for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Chronic hepatitis C and superimposed nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Risk factors of fibrosis in alcohol-induced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Factors predictive of liver cirrhosis in patients with chronic hepatitis B: a multivariate analysis in a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Association of diabetes mellitus and chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Effect of physiologic hyperinsulinemia on glucose and lipid metabolism in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Free radicals generated during the glycation reaction of amino acids by methylglyoxal. A model study of protein-cross-linked free radicals

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

HNE interacts directly with JNK isoforms in human hepatic stellate cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Prevention of fat-induced insulin resistance by salicylate

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900456-2

7 January 2021

10.1016/S0168-8278(03)00456-2

Identifiers

DOI

1 reference

30 November 2017

1 reference